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Abstract. Malaria continues to claim the lives of more children worldwide than any other infectious disease, and
improved understanding of disease immunology is a priority for the development of new therapeutic and vaccination
strategies. FcRIIa (CD32) contains a polymorphic variant (H/R131) that has been associated with variability in
susceptibility to both bacterial diseases and Plasmodium falciparum parasitemia. We investigated the role of this
polymorphism in West Africans with mild and severe malarial disease. The HH131 genotype was significantly associated
with susceptibility to severe malaria (P 0.03, odds ratio 1.40, 95% confidence interval 1.02−1.91). In contrast to
studies of parasitemia, the presence of the R131 allele, rather than the RR131 genotype, appeared to be the important
factor in protection from disease. This is the first evidence for an association between CD32 polymorphism and severe
malaria and provides an example of balancing selective pressures from different infectious diseases operating at the same
genetic locus.
INTRODUCTION
Malaria continues to claim the lives of more children world-
wide than any other infectious disease. A greater understand-
ing of the mechanisms of malarial immunity would aid con-
siderably the development of new therapeutic and vaccina-
tion strategies. The study of host genetics continues to
provide important insights into such mechanisms of protec-
tion and improve our understanding of the pathogenesis of
this complex disease.
The family of Fc receptors is believed to have an important
role in immunity to many infections, including malaria.
FcRIIa (CD32) is expressed on the surface of lymphocytes
and monocytes/macrophages, and the molecule provides an
important link between humoral and cellular immune sys-
tems. It is a low-affinity IgG receptor capable of binding im-
munoglobulin subtypes IgG1-4 and it is able to bind C-reactive
protein (CRP) with high affinity. However, both the recogni-
tion of IgG and CRP by CD32 are influenced by polymor-
phism within the gene.
A single nucleotide change within the CD32 molecule al-
ters a histidine (H) to an arginine (R) residue at position 131
and changes its function in vitro. The presence of the H131
allele is essential for the efficient binding of IgG2 subtypes.
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In its absence, those with the RR131 genotype have prefer-
ential affinity for IgG3 and IgG1 subtypes. In addition to the
differences in immunoglobulin affinity, the co-dominantly ex-
pressed H131 and R131 alleles differ in their ability to bind
CRP. The R131 allele appears to be a high-affinity receptor
for CRP, with the critical binding site lying near to that for
IgG,2 and the RR131 genotype has been shown to increase
susceptibility to meningococcal and pneumococcal disease.3−5
Both CRP and immunoglobulin appear to play a role in
malarial immunity. CRP has been shown to bind to Plasmo-
dium species in vitro and might have a role in protection
against the earliest stages of infection,6 whereas immunoglob-
ulin-transfer experiments have clearly demonstrated the im-
portance of antibody-mediated immunity to malarial parasit-
emia.7 Studies of protective antibody responses have shown
that protection from disease correlates with antigen-specific
IgG1 and, more particularly, IgG3 immunoglobulin subtypes
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that recognize specific malarial antigens including merozoite
surface protein-1 (MSP-1) and MSP-2.9,10 Furthermore, anti-
gen-specific titers of IgG2 specific for MSP-2 and glutamate-
rich protein have been positively correlated with protection
from malarial infection and disease.11,12 However, there re-
mains some uncertainty as to which of these IgG subclasses
might be more important in malarial immunity, and the func-
tional activity of these immunoglobulin subtypes is likely to
depend, at least in part, on the CD32 genotype of the host.
A recent birth cohort study in western Kenya observed that
the RR131 genotype offered protection against high levels of
P. falciparum parasitemia in the first year of life.13 In the only
study of CD32 and malarial disease to date, a non-significant
excess of HH131 homozygotes was seen in those with severe
disease.14 The objective of this study was to examine whether
CD32 polymorphism is associated with susceptibility to either
mild or severe P. falciparum disease in a large west African
cohort.
MATERIALS AND METHODS
Population. The subjects were recruited in The Gambia in
western Africa and the study population has been described
in detail elsewhere.15 This study was reviewed and approved
by the Gambian government/Medical Research Council joint
ethical committee. All subjects or the parents or guardians of
the children gave informed consent to participate in the study.
Subjects were children ranging in age from birth to 10 years
old (mean ± SD age  3.4 ± 2.1 years) and the burden of
severe malaria falls mainly on those less than five years of age
(81.8% of the severe cases and 80.5% of the controls were less
than five years old). Non-malarial controls were drawn from
those with mild disease (generally attending an out-patient
clinic for mild illness with a negative malaria blood film) and
severe disease (generally in-patients with mainly infectious,
non-malarial illnesses). Severe malaria was defined as the
presence of one or more of the following: 1) cerebral malaria
(Glasgow Coma Scale <3, or a prolonged seizure); 2) severe
malarial anemia (hemoglobin level <5 g/dL); and 3) hypogly-
cemia (glucose level <2.2 mM). Mild malaria cases had par-
asitemias >2,500/L. There was no significant difference in* These authors contributed equally to this work.
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the representation of each ethnic group for mild malaria, se-
vere malaria, or controls. Frequencies of ethnic groups were
Fula (9.1% mild malaria, 12.6% severe malaria, and 11.9%
controls), Jola (14.3%, 15.3%, and 13.8%), Mandinka
(49.3%, 41.9%, and 44.8%), Serrahuli (5.2%, 5.3%, and
4.5%), Wolof (10.2%, 14.7%, and 13.7%) and Manjago
(5.8%, 4.5%, and 5.9%).
Genotyping. The CD32 genotype was determined using a
modified version of previously published methods.16 The
polymerase chain reaction conditions were as follows: one
cycle at 96°C for five minutes, 35 cycles at 92°C for 40 seconds
and 55°C for 30 seconds, and one cycle at 72°C for 10 minutes.
Products were digested using Bst UI, which cuts once in the
presence of the R131 allele and twice in the presence of the
H131 allele. Fragments were resolved by electrophoresis on a
3% agarose gel.
Statistical analysis. Logistic regression analysis was per-
formed using SPSS version 11 (SPSS, Inc, Chicago, IL) and
included age, sex, geographic area of residence, and ethnicity
as cofactors. Using the same software, we performed an over-
all comparison of genotype frequency using a 3 × 2 chi-square
test and subsequent allele frequency using a 2 × 2 chi-square
test.
RESULTS
A total of 1,415 individuals were included in this study.
Three hundred thirty-three (23.5%) were diagnosed with
mild malaria, 524 (37.0%) with severe malaria, and 558
(39.4%) were non-malarial controls. Overall genotype fre-
quencies did not vary significantly between different ethnic
groups in the control population (P  0.26).
The HH131 genotype was at a higher frequency in those
with severe malaria compared with controls (26.3% for severe
malaria versus 21.7% for controls; P 0.065) (Table 1), and
this result was significant in those less than five years of age
(27.9% for severe malaria versus 21.9% for controls; odds
ratio [OR] 1.38, 95% confidence interval [CI] 1.0−1.90,
P 0.04). A similar trend was seen with each severe pheno-
type (24.2% for severe anemia and 25.6% for cerebral ma-
laria versus 21.7% for controls; P  0.68 and P  0.26, re-
spectively). The HH131 genotype was more common in those
with mild malaria than in controls, although this was not sta-
tistically significant (24% versus 21.7%, OR  1.14, 95% CI
 0.82−1.60, P  0.41). A higher frequency of HR131 het-
erozygotes was observed in the control group (50.9%) than
either the mild malaria (46.8%; P  0.45) or the severe ma-
laria group (44.7%; P  0.07). No significant difference was
seen in the frequency of RR131 genotype between those with
severe malaria and the controls, (28.6% for severe malaria
versus 28.0% for controls; P  0.81). Similar trends in data
were seen when analysis was restricted to infants less than one
year of age and when the phenotypes of severe malarial ane-
mia and cerebral malaria were considered separately.
Using a logistic regression model (taking into account eth-
nic group, geographic area, age, and sex), we found that the
HH131 genotype was significantly associated with severe ma-
larial disease (OR  1.40 95% CI  1.02−1.91, P  0.034)
(Table 2). This result was more significant when those less
than five years old were analyzed separately (OR 1.50 95%
CI  1.06−2.12, P  0.021).
DISCUSSION
These data demonstrate that the HH131 genotype is sig-
nificantly associated with increased susceptibility to severe
malarial disease in the West African population of The Gam-
bia. A similar trend was seen towards susceptibility to mild
malaria. The effect of this genotype was seen most clearly in
those less than five years of age, the age group which carries
the burden of severe disease in endemic areas, a finding con-
sistent with previous evidence of age dependent effects.3
Given current understanding of the functional differences
between H131 and R131 alleles, there are several potential
explanations for the observed disease association. Individuals
with the HH131 genotype have a low affinity for binding
CRP,2 and the susceptibility associated with this genotype is
consistent with previous evidence for a protective role of CRP
in malaria.6 However, in a region of high malarial endemicity,
CRP is likely to be less important than IgG in protection from
malarial disease.
In the presence of the HH131 genotype, IgG1, IgG2, and
IgG3 immunoglobulin subtypes are able to activate the im-
mune system using the FcRIIa molecule, and the presence of
the H131 allele is essential for effective IgG2-mediated cellu-
lar activation through this mechanism. There is accumulating
evidence that some IgG2 antigen-specific responses correlate
with disease protection, but one plausible interpretation of
these data is that the clinical importance of IgG2 subtypes is
less than that of IgG1 and IgG3. This is consistent with early
immuno-epidemiologic studies, which first found that disease
protection correlated most clearly with IgG1 and IgG3 anti-
gen-specific immunoglobulins.8 An alternative and more
speculative explanation for the findings could be that in the
presence of the HH131 genotype, a greater quantitative acti-
vation of the innate immune system can be achieved by a
broader repertoire of antibodies, increasing the risk of immu-
nopathology and disease.
Shi and others, in their study of infant parasitemia in East
Africa, observed that the RR131 genotype appeared to pro-
tect from high levels of parasitemia.13 We observed no evi-
dence for a protective effect of the RR131 genotype against
TABLE 1
CD32 genotype distribution according to malarial phenotype*
Genotype
Severe
malaria
Cerebral
malaria
Several malarial
anemia
Mild
malaria Controls
RR131 150 (28.6%) 94 (29.4%) 39 (29.5%) 97 (29.1%) 156 (28.0%)
HR131 236 (45.0%) 144 (45.0%) 61 (46.2%) 156 (46.8%) 281 (50.4%)
HH131 138 (26.3%) 82 (25.6%) 32 (24.2%) 80 (24.0%) 121 (21.7%)
Total 524 320 132 333 558
* Cerebral malaria and severe malarial anemia are subgroups of severe malaria.
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mild malaria or malarial disease in this West African popula-
tion. Rather, the data here suggest that it is the presence of
the R131 allele that is protective against severe malaria. This
discrepancy might well be due to differences in study design,
particularly the different phenotype studied, and the contrast-
ing sample sizes. In this study, children less than one year of
age showed a similar trend in genotype distribution to the
overall data set, suggesting that the age of study participants
is unlikely to be an explanation for the differing results. An
alternative possibility, in the absence of a protective effect
from the RR131 genotype, is that heterozygosity at this locus
might be protective against severe malaria. However, al-
though there is a consistent trend within the data sets, het-
erozygotes were not significantly more common among the
controls.
If the HH131 genotype alone was a major susceptibility
factor for severe malaria, it might be expected that the H131
allele would be at lower frequency than the 47% observed in
this population. However, the H131 allele might be playing an
important protective role in protection from other diseases,
particularly those caused by capsulated bacteria. Bredius and
others found that the RR131 genotype was more frequent
among survivors of severe meningococcal disease than in con-
trols,17 suggesting it might be a risk factor for severe disease.
A similar association was identified with severe meningococ-
cal disease3 (where the effect was only clearly seen in those
more than five years of age) and bacteremic pneumococcal
pneumonia.5 IgG2, which requires the presence of the H131
allele for efficient activity, is known to be important for pro-
tection from infection with capsulated bacteria including
Neisseria meningitidis, Streptococcus pneumoniae, and Hae-
mophilus influenzae,18 and a reduction in this opsonic capac-
ity is the most likely mechanism for genotypic effects ob-
served. These bacterial diseases cause significant mortality in
West Africa,19,20 and the data here suggest that these poten-
tially deleterious effects attributable to the R131 allele are, in
this population at least, partly balanced by a protective effect
against severe malaria.
The frequencies of the H131/R131 alleles differ signifi-
cantly between populations and the selective pressures re-
sponsible have been the subject of some debate. In Cauca-
sians in the United Kingdom, each allele is present at similar
frequency (47% for R131 versus 53% for H131, Segal S, un-
published data), figures typical of European populations21
and similar to those described here. In the Asian populations
of Japan and China, the R131 allele is comparatively rare
(22−28%) and invasive bacterial infections are relatively un-
common in populations of the Far East, an observation that
some have linked to the low frequency of the RR131 geno-
type.21 In regions where malaria is not endemic, it is possible
that the lack of this selective pressure has allowed the fre-
quency of the R131 allele to decrease relative to that of H131.
In summary, the association of HH131 genotype with se-
vere malaria offers insight into immune mechanisms that
might be important in protecting from severe malaria and
provides evidence of balancing forces of natural selection,
from different infectious diseases, operating at a single ge-
netic locus.
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